Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial
The greater reduction in HbA1c achieved with IDegAsp compared to IGlar in individuals with T2DM was associated with an impaired GLP-1 response, facilitating personalized insulin therapy.
Authors
- Kyong Soo Park (ORCID: https://orcid.org/0000-0003-3597-342X)
- Soo Heon Kwak (ORCID: https://orcid.org/0000-0003-1230-0919)
- Hye Seung Jung (ORCID: https://orcid.org/0000-0002-0221-7049)
- Seong Ok Lee
- Ye Yang (ORCID: https://orcid.org/0000-0001-9682-6138)
- Han Na Jang (ORCID: https://orcid.org/0000-0002-6186-2937)
- Hak Chul Jang (ORCID: https://orcid.org/0000-0002-4188-6536)
- Andrea Mari (ORCID: https://orcid.org/0000-0001-9070-5706)
- Myoung‐jin Jang (ORCID: https://orcid.org/0000-0001-8123-5001)
- Eun Shil Hong
Institutions
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- National Research Council (IT)
Publication Details
- Journal
- Diabetes & Metabolism Journal
- Published
- 2025-08-14
- DOI
- https://doi.org/10.4093/dmj.2024.0741
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00